EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992)
Evangeline Jackson, Ryan Duchatel, Dilana Staudt, Mika Persson, Abdul Mannan, Sridevi Yadavilli, Sarah Parackal, Shaye Game, Wai Chin Chong, W Samantha Jayasekara, Marion Le Grand, Padraic Kearney, Alicia Douglas, Izac Findlay, Zacary Germon, Holly McEwen, Tyrone Beitaki, Adjanie Patabendige, David Skerrett-byrne, Brett NixonNathan Smith, Bryan Day, Neevika Manoharan, Sumanth Nagabushan, Jordan Hansford, Dinisher Govender, Geoffrey McCowage, Ron Firestein, Meegan Howlett, Raelene Endersby, Nicholas Gottardo, Frank Alvaro, Sebastian Waszak, Martin Larsen, Yolanda Colino Sanguino, Fatima Valdes-Mora, Andria Rakotomalala, Samuel Meignan, Eddy Pasquier, Nicolas Andre, Esther Hulleman, David Eisenstat, Nicholas Vitanza, Javad Nazarian, Carl Koschmann, Sabine Mueller, Jason Cain, Matthew Dun
Research output: Contribution to journal › Article (journal) › peer-review
Fingerprint
Dive into the research topics of 'EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992)'. Together they form a unique fingerprint.